In the treatment of HER2-positive breast cancer, tucatinib, an effective selective HER2 tyrosine kinase inhibitor, increases the frequency of CD8+PD-1+ and CD8+TIM3+ T cells and CD49+ NK cells and synergizes with PD-1/PD-L1 inhibitors 188. This evidence concerns the gene ERBB2 and breast carcinoma.